BioVersys AG (XSWX:BIOV) EPS (Basic): CHF-3.89 (TTM As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.00
View Full Analysis

What is BioVersys AG EPS (Basic)?

BioVersys AG XSWX:BIOV +1.17% 4 EPS (Basic) is CHF-3.89 as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was CHF-1.84. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.89.

BioVersys AG's EPS (Diluted) for the six months ended in Dec. 2025 was CHF-1.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.89.

BioVersys AG's EPS without NRI for the six months ended in Dec. 2025 was CHF-1.88. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -3.92.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

BioVersys AG  (XSWX:BIOV) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BioVersys AG EPS (Basic) Related Terms

BioVersys AG EPS (Basic) Historical Data

* Premium members only.

The historical data trend for BioVersys AG's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG EPS (Basic) Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
EPS (Basic)
-3.17 -3.89

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
EPS (Basic) -1.75 -1.41 -2.05 -1.84
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

BioVersys AG's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-21.83-0)/5.615
=-3.89

BioVersys AG's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-10.82-0)/5.849
=-1.85

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-3.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of CHF-3.89 mean?
BioVersys AG (XSWX:BIOV) has a EPS (Basic) of CHF-3.89 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's EPS (Basic) too high?
BioVersys AG's current EPS (Basic) is CHF-3.89. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's EPS (Basic) compare to VRTX and REGN?
BioVersys AG's EPS (Basic) of CHF-3.89 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BioVersys AG and its competitors. BioVersys AG's current EPS (Basic) is CHF-3.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current EPS (Basic) of CHF-3.89. The current EPS (Basic) is CHF-3.89. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current EPS (Basic) is CHF-3.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.00
Price